Back to today’s briefing

Story perspectives

Breakthrough Treatments Transform Lives for ATTR-CM Patients

3/6/2025

35 5

Summary

Story summary

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare yet serious heart condition caused by misfolded proteins, resulting in heart failure. It comes in hereditary and wild-type forms. Promising treatments like tafamidis and the newly approved Attruby stabilize the proteins, while Amvuttra shows potential in lowering mortality rates and enhancing patients' quality of life.

1 of 1

Story summary

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare yet serious heart condition caused by misfolded proteins, resulting in heart failure. It comes in hereditary and wild-type forms. Promising treatments like tafamidis and the newly approved Attruby stabilize the proteins, while Amvuttra shows potential in lowering mortality rates and enhancing patients' quality of life.